Grants per year
- 1 - 25 out of 26 results
Search results
-
Active
Prot #CF33-CD19-101: A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumor
Mahalingam, D. (PD/PI)
Medpace Clinical Research LLC, Imugene Limited
8/9/24 → 8/9/27
Project: Research project
-
Prot #CP-MVC-101-01: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic
Mahalingam, D. (PD/PI)
PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.
4/22/24 → 4/22/27
Project: Research project
-
Prot #2138-CL-0101: A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Exp
Mahalingam, D. (PD/PI)
ICON Clinical Research, LLC, Astellas Pharma Global Development, Inc.
4/15/24 → 4/15/27
Project: Research project
-
Prot #M24-427: A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Mahalingam, D. (PD/PI)
3/13/24 → 3/13/27
Project: Research project
-
Prot #IMSA101-103: Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligoprogressive Solid Tumor Malignan
Mahalingam, D. (PD/PI)
Clinipace, Inc., ImmuneSensor Therapeutics, Inc.
12/15/23 → 12/15/26
Project: Research project
-
Prot #BA3182-001: An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
Mahalingam, D. (PD/PI)
Worldwide Clinical Trials, Inc., BioAtla, Inc
12/15/23 → 12/15/26
Project: Research project
-
Prot #QRNT‐009: A Phase 1/2 Multicenter, Open‐label, Dose‐escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Re
Mahalingam, D. (PD/PI)
Translational Drug Development, LLC, Qurient Co. Ltd.
6/1/23 → 6/1/26
Project: Research project
-
Prot #IO‐202‐CL‐002: A Phase 1, Multicenter, Open‐Label, Dose‐Escalation, and Dose‐Expansion Study of IO‐202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors
Mahalingam, D. (PD/PI)
Ergomed Clinical Research Inc., Immune‐Onc Therapeutics, Inc.
4/25/23 → 4/25/26
Project: Research project
-
Prot #OM-GRPR1-02: A Phase 1 Open-Label Dose Escal
Mahalingam, D. (PD/PI)
Medpace Clinical Research LLC, Orano Med, LLC
3/16/23 → 3/16/26
Project: Research project
-
Prot #ADCT-901-101: A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
Mahalingam, D. (PD/PI)
Clinipace, Inc., ADC Therapeutics Sarl
4/27/22 → 4/27/25
Project: Research project
-
Prot #BNT152-01C: Phase I, First-In-Human, Open-Label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of BNT152+153 in Patients with Solid Tumors
Mahalingam, D. (PD/PI)
ICON Clinical Research, LLC, BioNTech SE
3/18/22 → 3/18/25
Project: Research project
-
Prot #RP-3500-01: Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations (TR
Mahalingam, D. (PD/PI)
1/19/22 → 1/19/25
Project: Research project
-
Prot #DT2216-001: A Phase 1, Open-Label, Dose Escalation, And Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics (PK) And Clinical Activity Of DT2216, An Antiapoptotic Protein Targeted Degradation Compound, In Subjects With Rela
Mahalingam, D. (PD/PI)
SCRI Development Innovations, LLC, Dialectic Therapeutics, Inc.
1/5/22 → 1/5/25
Project: Research project
-
Prot #DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First- Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Ju
Mahalingam, D. (PD/PI)
Novotech Clinical Research USA, LLC, Leap Therapeutics, Inc.
2/10/21 → 2/10/27
Project: Research project
-
Prot #Q702-ONC-P1-US001: A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
Mahalingam, D. (PD/PI)
Translational Drug Development, LLC, Qurient Co. Ltd.
1/20/21 → 1/20/27
Project: Research project
-
Prot #BNT411-01: Phase 1/2a, First-In-Human, Open-label, Dose-escalation Trial With Expansion Cohorts To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy Of BNT411 As A Monotherapy In Patients With Solid Tumors And In Combinat
Mahalingam, D. (PD/PI)
ICON plc, BioNTech Small Molecules GmbH
5/27/20 → 5/27/26
Project: Research project
-
Prot #18-0402: A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, In Subjects With Advanced Solid Tumors And Pancreatic Cancer Using Combination Therapy
Mahalingam, D. (PD/PI)
Novella Clinical, LLC, NGM Biopharmaceuticals, Inc.
3/17/20 → 3/17/26
Project: Research project
-
North American Star Consortium
Mahalingam, D. (PD/PI), Mahalingam, D. (PD/PI), Sosman, J. A. (PD/PI), Sosman, J. A. (Co-PD/PI), Sosman, J. A. (Co-PD/PI), Kumthekar, P. U. (Co-Investigator), Kumthekar, P. U. (Co-Investigator), VanderWeele, D. J. (Co-Investigator) & VanderWeele, D. J. (Co-Investigator)
University Health Network (Toronto), National Cancer Institute
3/1/20 → 2/28/26
Project: Research project
-
Prot #IMSA101-101: Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients with Advanced Treatment-Refractory Malignancies
Mahalingam, D. (PD/PI)
Precision Oncology, LLC, ImmuneSensor Therapeutics, Inc.
12/13/19 → 12/13/25
Project: Research project